Macquarie Group Ltd. Increases Position in Vanda Pharmaceuticals Inc. (VNDA)

Macquarie Group Ltd. boosted its position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 8.8% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 1,703,559 shares of the biopharmaceutical company’s stock after acquiring an additional 138,278 shares during the period. Macquarie Group Ltd. owned 3.80% of Vanda Pharmaceuticals worth $27,768,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in VNDA. Legal & General Group Plc raised its stake in Vanda Pharmaceuticals by 37.4% in the 2nd quarter. Legal & General Group Plc now owns 11,105 shares of the biopharmaceutical company’s stock valued at $181,000 after acquiring an additional 3,022 shares during the period. Virginia Retirement Systems ET AL bought a new stake in Vanda Pharmaceuticals in the 1st quarter valued at about $193,000. Dynamic Technology Lab Private Ltd bought a new stake in Vanda Pharmaceuticals in the 1st quarter valued at about $196,000. Kopp Investment Advisors LLC bought a new stake in Vanda Pharmaceuticals in the 2nd quarter valued at about $196,000. Finally, American International Group Inc. raised its stake in Vanda Pharmaceuticals by 7.1% in the 1st quarter. American International Group Inc. now owns 22,563 shares of the biopharmaceutical company’s stock valued at $316,000 after acquiring an additional 1,491 shares during the period. Institutional investors and hedge funds own 86.49% of the company’s stock.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) opened at 16.80 on Wednesday. The firm’s 50-day moving average price is $17.45 and its 200-day moving average price is $15.62. The stock’s market cap is $753.61 million. Vanda Pharmaceuticals Inc. has a 12-month low of $12.70 and a 12-month high of $18.99.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.18. Vanda Pharmaceuticals had a negative return on equity of 7.85% and a negative net margin of 6.54%. The firm had revenue of $42.06 million for the quarter, compared to the consensus estimate of $40.31 million. During the same quarter last year, the company earned $0.01 earnings per share. The business’s revenue for the quarter was up 16.7% compared to the same quarter last year. On average, equities analysts predict that Vanda Pharmaceuticals Inc. will post ($0.43) EPS for the current fiscal year.

A number of equities research analysts recently issued reports on VNDA shares. Zacks Investment Research cut Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 18th. Jefferies Group LLC restated a “buy” rating and issued a $21.00 price objective on shares of Vanda Pharmaceuticals in a research note on Tuesday, August 29th. Piper Jaffray Companies boosted their price objective on Vanda Pharmaceuticals from $23.00 to $26.00 and gave the company an “overweight” rating in a research note on Thursday, September 14th. BidaskClub upgraded Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, August 22nd. Finally, Oppenheimer Holdings, Inc. restated a “buy” rating and issued a $21.00 price objective on shares of Vanda Pharmaceuticals in a research note on Thursday, September 14th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $21.29.

COPYRIGHT VIOLATION WARNING: This report was originally published by Week Herald and is the property of of Week Herald. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at https://weekherald.com/2017/10/11/macquarie-group-ltd-increases-position-in-vanda-pharmaceuticals-inc-vnda.html.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Institutional Ownership by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply